Search Results - Bijoyesh Mookerjee

Refine Results
  1. 1
    Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase.

    Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. by Xuenong Luo, Bijoyesh Mookerjee, Anna C. Ferrari, Sucharita J. Mistry, George F. Atweh

    Published 1994
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir

    Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir by Dionysios Neofytos, Ambrish Ojha, Bijoyesh Mookerjee, John Wagner, Joanne Filicko, Andres Ferbér, Scott Dessain, Dolores Grosso, Janet Brunner, Neal Flomenberg, Phyllis Flomenberg

    Published 2007
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α

    Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α by Rajani Ravi, Bijoyesh Mookerjee, Zaver M. Bhujwalla, Thomas R. Sutter, Dmitri Artemov, Qinwen Zeng, Larry E. Dillehay, Ashima Madan, Gregg L. Semenza, Atul Bedi

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial by David Planchard, Egbert F. Smit, Harry J.M. Groen, Julien Mazières, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

    Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON I... by Hans‐Joachim Schmoll, David Cunningham, Alberto Sobrero, Christos S. Karapetis, Philippe Rougier, Sheryl Koski, Ilona Kocáková, Igor Bondarenko, G. Bodoky, Paul N. Mainwaring, Ramón Salazar, Peter Barker, Bijoyesh Mookerjee, Jane Robertson, Eric Van Cutsem

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer

    Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer by Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean Charles Soria, Patrick Y. Wen, Christoph Zielinski, Maria E. Cabanillas, Gladys Urbanowitz, Bijoyesh Mookerjee, Dazhe Wang, Fatima Rangwala, Bhumsuk Keam

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing

    A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing by Dolores Grosso, Matthew Carabasi, Joanne Filicko-O’Hara, Margaret Kasner, John L. Wagner, Beth Colombe, Patricia Cornett Farley, William O’Hara, Phyllis Flomenberg, Maria Werner‐Wasik, Janet Brunner, Bijoyesh Mookerjee, Terry Hyslop, Mark A. Weiss, Neal Flomenberg

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma

    Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma by Caroline Robert, Keith T. Flaherty, Paul Nathan, Peter Hersey, Claus Garbe, Mohammed Milhem, Lev Demidov, Peter Mohr, Jessica C. Hassel, Piotr Rutkowski, Reinhard Dummer, Jochen Utikal, Felix Kiecker, James Larkin, Anthony M. D’Amelio, Bijoyesh Mookerjee, Dirk Schadendorf

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma

    Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastat... by Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, Daniil Stroyakovskiy, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Bijoyesh Mookerjee, Jeffery J. Legos, Y. Zhang, Stephen Lane, Dirk Schadendorf

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    P2.01-02 CANOPY-A: A Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC

    P2.01-02 CANOPY-A: A Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC by Edward B. Garon, Andrea Ardizzoni, Fabrice Barlési, Byoung Chul Cho, Pedro De Marchi, Yasushi Goto, Lu Shen, Luis Paz‐Ares, David R. Spigel, M. Thomas, Bijoyesh Mookerjee, Pilar Cazorla Arratia, Jason Baum, Zewen Zhu, James Chih‐Hsin Yang

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

    A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea by Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter J. Rosen, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Paola Guglielmelli, Chiara Elena, Shui He, Nancy Contel, Bijoyesh Mookerjee, Victor Sandor, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

    Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma by Antoni Ribas, Donald P. Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H. Miller, Matteo S. Carlino, Rosalie Fisher, Georgina V. Long, F. Stephen Hodi, Jennifer Tsoi, Catherine S. Grasso, Bijoyesh Mookerjee, Qing Zhao, Razi Ghori, Blanca Homet Moreno, Nageatte Ibrahim, Omid Hamid

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    PD01.04 CANOPY-A: a Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC

    PD01.04 CANOPY-A: a Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC by David R. Spigel, E.B. Garon, Andrea Ardizzoni, Fabrice Barlési, Byoung Chul Cho, Pedro De Marchi, Yasushi Goto, Sheng Lu, Luis Paz‐Ares, M. Thomas, Bijoyesh Mookerjee, Mimi Leung, Joel A. C. Baum, Z. Zewen, J.C.-H. Yang

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

    Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL) by Robert J. Kreitman, Philippe Moreau, Martin Hutchings, Anas Gazzah, Jean‐Yves Blay, Zev A. Wainberg, Alexander Stein, Sascha Dietrich, Maja J.A. de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Farhad Ravandi, Fatima Rangwala, Paul Burgess, Bijoyesh Mookerjee, Vivek Subbiah

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

    Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial by David Planchard, Benjamin Besse, Harry J.M. Groen, Pierre-Jean Souquet, Élisabeth Quoix, Christina S. Baik, Fabrice Barlési, Tae Min Kim, Julien Mazières, Silvia Novello, James R. Rigas, Allison Upalawanna, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Activity &amp; safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, &amp; gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

    Activity &amp; safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, &amp... by James C. Yao, Jonathan Strosberg, Nicola Fazio, Marianne Pavel, Philippe Ruszniewski, Emily K. Bergsland, D. Li, Salvatore Tafuto, Nitya Raj, Davide Campana, Susumu Hijioka, Markus Raderer, Rosine Guimbaud, Pablo Gajate, Sara Pusceddu, Albert Reising, Evgeny Degtyarev, Bijoyesh Mookerjee, Paola Aimone, Simron Singh

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

    Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials by Axel Hauschild, Paolo A. Ascierto, Dirk Schadendorf, Jean‐Jacques Grob, Antoni Ribas, Felix Kiecker, Caroline Dutriaux, Lev Demidov, Célèste Lebbé, Piotr Rutkowski, Christian U. Blank, Ralf Gutzmer, Michael Millward, Richard Kefford, T Haas, Anthony M. D’Amelio, Eduard Gasal, Bijoyesh Mookerjee, Paul B. Chapman

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

    Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial by Michael A. Davies, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Keith T. Flaherty, Ana Arance, Vanna Chiarion‐Sileni, L. Thomas, Thierry Lesimple, Laurent Mortier, Stergios J. Moschos, David Hogg, Iván Márquez‐Rodas, Michele Del Vecchio, Célèste Lebbé, Nicolás Meyer, Ying Zhang, Yingjie Huang, Bijoyesh Mookerjee, Georgina V. Long

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Long-Term Outcomes in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

    Long-Term Outcomes in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib by Georgina V. Long, Zeynep Eroglu, Jeffrey R. Infante, Sapna P. Patel, Adil Daud, Douglas B. Johnson, René González, Richard Kefford, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, William H. Sharfman, Robert R. McWilliams, Mario Sznol, Suman Redhu, Eduard Gasal, Bijoyesh Mookerjee, Jeffrey S. Weber, Keith T. Flaherty

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma

    KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma by Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Stephens, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar‐Sela, Félix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno, Antoni Ribas

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: